Early trial tests 'Universal' cell therapy for devastating lupus
NCT ID NCT07031713
Summary
This is an early-stage study testing a new type of cell therapy for people with moderate to severe lupus that hasn't responded to standard treatments. The therapy, called CT1192, involves giving patients specially modified immune cells (CAR-T cells) designed to target and remove the harmful B cells thought to drive lupus. The main goals are to find a safe dose and see how the body handles the cells, while also checking if it helps control the disease.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Wuhan Union Hospita
RECRUITINGWuhan, Hubei, 430000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.